Search

everythinglearnresearchcommunity

for

Search:↓

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

A user tried topical melatonin for hair loss and experienced significantly reduced shedding, similar to when they used finasteride, but stopped finasteride due to side effects. They applied liquid melatonin from a dropper and noticed a decrease in hair fall within two days.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

A user has been using finasteride and minoxidil for hair loss but is experiencing increased shedding and is considering using topical melatonin with a product called Rizn. Another user is skeptical about the effectiveness of topical melatonin due to issues with the research and lack of replication of results, while a third user expresses interest in the outcome of using Rizn after not seeing results from topical finasteride and minoxidil.

The conversation discusses the effectiveness of topical Rapamycin for hair regrowth and color restoration. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

The conversation is about sourcing and using topical melatonin for retrograde alopecia. Users discuss purchasing options and potential benefits for hair growth.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.

A user reported less hair shedding using melatonin spray and is considering trying topical oxytocin or estrogel for hair growth, but is concerned about potential side effects like breast development. Topical oxytocin has been found to promote hair growth by increasing growth factors.

The user started using topical latanoprost and dutasteride, experiencing significant hair shedding and scalp itchiness, possibly due to an allergic reaction. They are considering stopping the treatment if the shedding is linked to an allergy.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

The conversation is about a user trying topical melatonin mixed with minoxidil to reduce hair shedding after not seeing desired results with finasteride and minoxidil alone. Another user suggests that instead of daily updates, the original poster should share their results after a few weeks.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.

Adding melatonin to minoxidil can improve hair growth and thickness, and it's easy to use with minimal side effects. The recommended concentration for melatonin in the solution is between 0.05% and 0.2%.

Bimatoprost (Latisse) shows promise in treating scalp alopecia. Users discuss its potential alongside Minoxidil, finasteride, and RU58841.

A user shared a new hair loss treatment protocol including topical dutasteride, latanoprost, caffeine, minoxidil, tretinoin, and triamcinolone acetonide. Others discussed the effectiveness and availability of these treatments, with some suggesting simpler oral alternatives.

OP is using 5% minoxidil and a foligain supplement for hair loss, with blood test results showing high cortisol levels. OP is considering starting finasteride, while another user shares their experience with finasteride and hair loss challenges due to malabsorption issues.

The conversation discusses using topical melatonin as a treatment for hair loss, with one person considering adding it to their minoxidil solution and another sharing their experience of no hair shedding, possibly due to melatonin.

Bimatoprost was discussed for hair loss, with concerns about long-term scalp effects. A user reported no substantial effect after 6 months of use.

The conversation is about creating a topical melatonin treatment for hair loss. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.

Progesterone cream might help with hair loss by inhibiting DHT production and suppressing prolactin, which can increase DHT. Some dermatologists have used progesterone for hair loss treatment, and it has been effective, sometimes combined with minoxidil, finasteride, and hydrocortisone.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

The conversation is about the potential benefits of Rapamycin for hair pigmentation and regeneration, based on effects observed in mice. The original poster is seeking personal experiences from others using Rapamycin for longevity.